Phase 2 study of ceritinib in ALKi-naive patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)

被引：9
|
作者：
Felip, E. [1 ]
Orlov, S. [2 ]
Park, K. [3 ]
Yu, C-J. [4 ]
Tsai, C-M. [5 ]
Nishio, M. [6 ]
Dols, M. C. [7 ]
McKeage, M. [8 ]
Su, W-C. [9 ]
Mok, T. S. K. [10 ]
Scagliotti, G. [11 ]
Spigel, D. R. [12 ]
Passos, V. Q. [13 ]
Chen, V. [13 ]
Munarini, F. [14 ]
Shaw, A. [15 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Inst Oncol, Barcelona, Spain
[2] Pavlov State Med Univ St Petersburg, Thorac Oncol, St Petersburg, Russia
[3] Innovat Canc Med Inst, Hematol Oncol, Seoul, South Korea
[4] Natl Taiwan Univ, Internal Med, Coll Med, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Thorac Oncol, Taipei, Taiwan
[6] JFCR, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan
[7] Hosp Univ Malaga Gen Carlos Haya, Med Oncol, Malaga, Spain
[8] Univ Auckland, Clin Pharmacol, Auckland, New Zealand
[9] Natl Cheng Kung Univ Hosp, Internal Med, Tainan, Taiwan
[10] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[11] Univ Turin, Oncol, Orbassano, Italy
[12] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[13] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
[14] Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland
[15] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1208O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Tsai, Chun-Ming
    Nishio, Makoto
    Dols, Manuel Cobo
    McKeage, Mark James
    Su, Wu-Chou
    Mok, Tony
    Scagliotti, Giorgio V.
    Spigel, David
    Branle, Fabrice
    Emeremni, Chetachi
    Quadrigli, Massimiliano
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK plus ) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and-3.
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Mehra, Ranee
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio V.
    Spigel, David R.
    Sutradhar, Santosh
    Cesic, Dajana
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [4] Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3
    Park, K.
    Tan, D.
    Ahn, M. -J.
    Yu, C. -J.
    Tsai, C. -M.
    Hida, T.
    Nishio, M.
    Branle, F.
    Emeremni, C.
    Mok, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 126 - 127
  • [5] WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK plus ) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND-3
    Mehra, Ranee
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio V.
    Spigel, David R.
    Sutradhar, Santosh
    Cesic, Dajana
    Shaw, Alice Tsang
    NEURO-ONCOLOGY, 2016, 18 : 28 - 29
  • [6] Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials
    Felip, E.
    Crino, L.
    Kim, D. -W.
    Spigel, D. R.
    Nishio, M.
    Mok, T.
    Scagliotti, G.
    Cesic, D.
    Sutradhar, S.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S118 - S119
  • [7] Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain
    Chow, L. Q.
    Barlesi, F.
    Bertino, E. M.
    van den Bent, M. J.
    Wakelee, H.
    Wen, P. Y.
    Chiu, C-H.
    Orlov, S.
    Majem, M.
    Chiari, R.
    McKeage, M.
    Yu, C-J.
    Hurtado, F. K.
    Arratia, P. Cazorla
    Song, Y.
    Branle, F.
    Shi, M.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2019, 30 : 602 - 603
  • [8] CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
    Shaw, Alice
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Geraldes, Margarida
    Sen, Paramita
    Boral, Anthony J.
    Yovine, Alejandro
    Kim, Dong-Wan
    NEURO-ONCOLOGY, 2014, 16
  • [9] The phase II ASCEND-7 (CLDK378A2205) trial: Ceritinib in patients (pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) metastatic to the brain and/or leptomeninges
    Wolf, J.
    Schneider, C-P
    Potzner, M.
    Arratia, Cazorla P.
    Shen, J.
    Branle, F.
    von Pawel, J.
    Oncology Research and Treatment, 2015, 38 : 138 - 138
  • [10] Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
    Nishio, Makoto
    Felip, Enriqueta
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Tsai, Chun-Ming
    Cobo, Manuel
    McKeage, Mark
    Su, Wu-Chou
    Mok, Tony
    Scagliotti, Giorgio V.
    Spigel, David R.
    Viraswami-Appanna, Kalyanee
    Chen, Zhe
    Passos, Vanessa Q.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 609 - 617
12345